HOPA Practice Management Course 2017


Registration Information


Preconference Session: Investigational Drug Services 0465-0000-17-066-L04-P

IDS: We Love Logistics

This is an overview of how the IU Health Investigational Drug Service (IDS) Team provides research medications to ten different physical locations in Indianapolis. The presentation will describe the changing role, priorities and responsibilities of an IDS Pharmacy in a growing health system. Topics to be discussed include documentation solutions, medication transport and remote staff education/training.

Learning Objectives:

  • Describe logistical tools and strategies to allow for a centralized Investigational Drugs Service.
  • Identify methods for managing research drug accountability and documentation across multiple sites.
  • Explain tactics to financially support the development and/or expansion of a centralized Investigational Drugs Service.

Clinical Practice in Investigational Drug Service

Present a single institute’s perspective on clinical pharmacy services that can be provided by an Investigational Drug Service. The session will provide a brief overview of Roswell Park Cancer Institute IDS pharmacy clinical practice, with emphasis on Early Phase Clinical Trials, present templates their IDS uses to standardize clinical practice within the group and discuss how other can apply or modify their procedures for their site.

Learning Objectives:

  • Describe responsibilities of a clinical pharmacist in an IDS
  • Provide overview of methods for documentation and quality assurance
  • Identify methods for increasing patient safety in clinical research
  • Define benchmarking data in an IDS

ADCC Pharmacy Committee on IDS Standards and Procedures

Learning Objectives:

  • Provide overview of HOPA IDS Best Practice Standards
  • Provide overview on ADCC Pharmacy Committee on IDS Standards and Procedures
  • Describe Investigational Pharmacy Services Metrics Data Capture

Attend just the Preconference or add the Preconference session to your conference registration!

There are additonal fees for either option.

Preconference only registration: $100. Add preconference to full registration: $75.


Christopher Lowe

Christopher Lowe, PharmD BCPS


Kathy Galus

Kathy Galus, PharmD BCOP


Sapna Amin

Sapna Amin, PharmD BCOP


The Ascendancy in Influence of Clinical Pharmacy Leaders in an Evolving Cancer Care World

Bill McGivney

Bill McGivney, PhD
McGivney Global Advisors LLC

Oncology Care Model/Medicare Access and CHIP Reauthorization Act 0465-0000-17-067-L04-P

Oncology Care Model

This presentation will include a description and overview of the Centers for Medicare/Medicaid Innovation (CMMI) Oncology Care Model. This will include what are the requirements for participation, what are the reporting requirements, the quality metrics that are being analyzed, how this program relates to MACRA; and how practices and organizations transform their workflow and processes to be successful in this model.

Learning Objectives:

  • Review and be able to articulate the requirements needed to participate in the Oncology Care Model (OCM)
  • Discuss the goals of the OCM and identify areas of transformation required by practices to succeed
  • Learn how the OCM relates to MACRA
  • Obtain information on the quality metrics required for reporting within OCM and data submission requirements

A New Paradigm in Cancer Care Reimbursement: An Update on OCM & MACRA

This presentation cover the background leading up to the creation of MACRA. It will describe how Medicare pays now to how Medicare with pay under MACRA. The program will describe the two primary payment strategies of MIPS and APM. The program will also provide what the timeline for implementation and payments will be and what will be measured. The program will also describe what the implications will be for institutions who participate to varying degrees. Final, the program will highlight some opportunities that MACRA may create for oncology pharmacy as a key team member.

Learning Objectives:

  • Describe the impetus for MACRA
  • Differentiate as to how Medicare pays now to how they will pay under MACRA
  • List the 2 primary payment strategies that MACRA will use
  • Describe the timeline for MACRA’s implementation and pay rates
  • List 3 opportunities MACRA may create for oncology pharmacy


Steve DAmato

Steven D’Amato, PharmD BSPharm RPh BCOP


Jim Koeller

Jim Koeller, MS

White Bagging/Brown Bagging – Challenges and Solutions 0465-0000-17-068-L04-P

This session will present the results from the recent HOPA White/Brown/Clear Bagging membership survey including a discussion of the current status on this issue. The faculty will cover the pros and cons of the three practices and will even highlight HOPA’s Health Policy work and use some regional examples of best practice.


Timothy Tyler

Timothy Tyler, PharmD

 sarah hudson disalle

Sarah Hudson-Disalle, PharmD RPh

HOPA Brown Bagging/White Bagging Workgroup

Oral Chemotherapy 0465-0000-17-069-L04-P

Justification and Development of an Oral Chemotherapy Service with an In-House Specialty Pharmacy

This session will describe the implementation of an oral chemotherapy service at an academic medical center with an internal specialty pharmacy. At our center, these initiation and monitoring services are provided by oncology clinical pharmacy specialists who are integrated along disease-state lines. Over the past two years, this program has justified six new clinical specialist positions in collaboration with our internal specialty pharmacy. This presentation will include a discussion of the metrics which have been monitored to expand the program rapidly in a short time period.

Learning Objectives:

  • Describe how an internal specialty pharmacy can be utilized for pharmacy position justification
  • Discuss the initial development, clinical metrics and financial metrics for an oral chemotherapy service with an in-house specialty pharmacy.

Oncology Clinical Pharmacist Working with Specialty Pharmacy for Oral Oncology Patients

This session will focus how a clinical pharmacist in the outpatient setting can work directly with an inhouse specialty pharmacy and assist in specialty accreditation. In addition, explore successful ways to work with specialty pharmacy that is not on site.

Learning Objectives:

  • Briefly discuss the pharmacist managed oral oncology program at University of Minnesota/Fairview Pharmacy Services
  • Review standard documentation pieces such as flowsheets and progress notes using EPIC functionality and how these relate to Specialty Pharmacy accreditation standards, such as URAC.
  • Provide key ideas and themes on how to work an oral oncology program with offsite Specialty Pharmacy.

Monitoring and Follow-Up of Patients on Oral Anticancer Agents: A Multidisciplinary Standardized Approach

There’s is a paucity of evidence – or practice-based data to guide the monitoring and follow-up of patients receiving oral anticancer agents. Given the high risk nature of these drugs, requirement for close laboratory and toxicity monitoring, and reliance on patient/caregiver administration, it is necessary for ambulatory oncology clinics to implement a standardized program for monitoring and follow-up of these patients. This session intends to discuss the implementation of a multidisciplinary  standardized process for patient monitoring focused on the ambulatory setting without an on-site specialty pharmacy (although applicable to other settings). This includes the use of scripted drug-specific toxicity assessment forms specific to a particular oral anticancer agent or class. These forms were generated by oncology clinical pharmacy specialists to aid in the consistent identification and monitoring for potential adverse effects, ensure compliance with laboratory monitoring parameters, and monitor patient adherence and self-administration techniques. This session will also discuss the standardized time points for follow-up with patients/caregivers. Strategies to overcome the monitoring and follow-up issues frequently faced by the health care providers in caring for patients on oral anticancer agents will be addressed.

Learning Objectives:

  • Differentiate the roles of multidisciplinary health care providers in the ongoing monitoring and follow-up of patients receiving oral anticancer agents.
  • Discuss the generation and utilization of drug-specific toxicity assessment forms.
  • Outline the standardized process for follow-up of patients receiving oral anticancer agents including adherence and toxicity assessment at pre-specified time points.


Victoria Brown

Victoria Brown, PharmD BCOP


Rebecca Fahrenbruch

Rebecca Fahrenbruch, PharmD BCOP


Danielle Roman

Danielle Roman, PharmD BCOP

Position Justification 0465-0000-17-070-L04-P

Outpatient Oncology Productivity Modeling

This presentation will provide a comprehensive background for pharmacy productivity models, a regional health system’s approach to a novel productivity model utilizing CPT codes and future applications for pharmacies.

Learning Objectives:

  • Review existing literature for pharmacy productivity models in the outpatient setting
  • Illustrate a novel outpatient infusion productivity metric for the health-system level
  • Compare the application of the productivity metric to scenarios

A Simple Approach: Budgets and Expansion of Services

This presentation will summarize budget strategies that have been implemented in a community health system for an oncology pharmacy to justify the expansion of oncology pharmacy services. The presentation will provide evidence based strategies to strengthen the financial performance of the department.

Learning Objectives:

  • Review financial planning strategies to incorporate USP800 requirements​.
  • Demonstrate techniques to maximize revenue budgeting.
  • Review strategies used to expand oncology pharmacy services.


Andrea Ledford

Andrea Ledford, PharmD BCOP


Jeff Reichard

Jeff Reichard, PharmD

<USP 800> 0465-0000-17-071-L04-P

Preparing for Implementation of USP Chapter 800

Organizations continue to prepare for implementation of USP Chapter <800>, effective July 1, 2018. This session will highlight the required changes of USP Chapter <800> focusing on implementation and some challenges from the perspective of two large multi-hospital healthcare systems. Topics include developing an algorithm for identifying hazardous drugs, risk containment strategies, facilities design, personal protective equipment (PPE) selection and environmental sampling.

Learning Objectives:

  • Explain relevant sections of USP Chapter 800 and NIOSH.
  • Describe an organizational strategy for handling, storage and disposal of hazardous drugs.
  • Come the differences between the approaches taken by two health-systems on implementation of USP 800.


corbin bennet

Corbin Bennett, PharmD MPH 


Jennifer Reddy

Jennifer Reddy, PharmD BCOP


IV Technology 0465-0000-17-072-L04-P

Improving Safety and Visibility in Hazardous Medication Preparation Through IV Automation

This session will review one medical center’s 4 year experience with IV hazardous medication automation in both a clinic setting and inpatient setting. Important considerations about IV automation and workflow will be reviewed from installation, optimization, and expansion of automation footprint.

Learning Objectives:

  • Identify key reasons for implementing hazardous IV compounding robotics​.
  • Review selection criteria for choosing a specific IV automation solution.
  • Predict potential challenges in implementing hazardous IV compounding robotics in their practice.
  • Describe current limitations of IV robotics

Improving Medication Safety through Innovation Strategies from Telepharmacy IV Workflow and Robotics

 Learning Objectives

  • Identify how the use of innovative and emerging technologies can support the expansion of pharmacy and pharmacist-related services.
  • Demonstrate how the use of a telepharmacy care model at a large Cancer Hospital has improved efficiency and optimization.
  • Understand the advantages and challenges of implementing a new robotic technology for hazardous IV compounding.
  • Understand how robotic technology can improve operational efficiencies and employee safety through reduced exposure to hazardous materials.

How accurate are your sterile preparations? The Use of Gravimetric Technology in Sterile Hazardous Preparations



Joseph Bonkowski

Joseph Bonkowski, PharmD MHA MS


Howard Cohen

Howard Cohen, MS RPh FASHP


Lindsey Amerine

Lindsey Amerine, PharmD MS BCPS 

Electronic Medical Records 0465-0000-17-073-L04-P

EPIC: Using an Electronic Medical Record for the Management of Oral Chemotherapy Patients

This session will focus on the utilization of EPIC technology in the management of oral chemotherapy patients. Order set and protocol development for oral oncology patients and standard documentation pieces such as flowsheets and progress notes will be covered.

Learning Objectives:

  • Briefly discuss the pharmacist managed oral oncology program at University of Minnesota/Fairview Pharmacy Services
  • Explain order set/protocol development for oral oncology patients in EPIC
  • Describe the use and development of an electronic patient list in EPIC for organization of patients on an oral chemotherapy program
  • Review standard documentation pieces such as flowsheets and progress notes using EPIC functionality

Prior Authorizations in Beacon

Current trends show that both the cost of drugs and the off-label use of drugs are at an all-time high, with expectations that it will continue to rise, especially in the oncology setting. This makes it even more important for healthcare systems to continue to obtain timely prior authorizations to prevent financial losses while caring for patients. This presentation will focus on how to integrate the Prior Authorization Process with an electronic medical record.

Learning Objectives:

  • Explain the Prior Authorization process and its importance.
  • Discuss how to implement the process in Epic and integrate it with Beacon
  • Discuss lessons learned.


Rebecca Fahrenbrunch

Rebecca Fahrenbrunch, PharmD BCOP



Janinah Barreto Hernandez, PharmD MS

Summary of Drug Waste Summit 0465-0000-17-074-L04-P

In 2016 Dr. Peter Bach and colleagues from Memorial Sloan Kettering Cancer Center in New York published a landmark paper in The BMJ describing the financial burden of cancer drug waste. Several factors specific to drug manufacturing practices, prescribing patterns, product preparation and billing systems were noted to contribute to the generation of drug waste. Yet the identification of rationale interventions to ameliorate drug waste in cancer care remains lacking. HOPA hosted its inaugural Policy Summit in May 2017 in Washington DC, convening stakeholders to discuss the problem in more detail and propose viable solutions. This session will highlight key findings of the summit.

Learning Objectives

  • Describe factors contributing to the generation of drug waste in the US
  • Identify approaches to reduce the burden of drug waste on the US health care system


Susannah Koontz

Susannah Koontz, PharmD BCOP FHOPA